Stocks Health care INDV
NASDAQ · Health careIndivior Pharmaceuticals, Inc. (INDV)
Indivior Pharmaceuticals, Inc. brought in $1.4B of revenue over the twelve months to September 30, 2026. Net income was $451M, a net margin of 32.8%. In fiscal 2025 capital spending exceeded operating cash flow by $93M. At September 30, 2026 it held $305M in cash against $488M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Indivior Pharmaceuticals, Inc.
- Net worth
- Indivior Pharmaceuticals, Inc. has a market value (market cap) of $4.5B at the latest share price, and shareholders' equity of -$60M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.2B (+4.3% year on year), with net income of $210M. Over the 12 months to September 30, 2026: revenue $1.4B, net income $451M.
- Cash flow
- In fiscal 2025 operations used $27M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Indivior Pharmaceuticals, Inc.'s next report is expected around January 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Indivior Pharmaceuticals, Inc. does
Indivior Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INDV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.2B | $210M | $1.64 | -$93M |
| 2024 | $1.2B | $7M | $0.05 | $7M |
| 2023 | $1.1B | -$126M | -$0.92 | -$308M |
| 2023 | $901M | -$44M | -$0.32 | -$9M |
| 2021 | $791M | $205M | n/a | $349M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where INDV ranks in Health care
Latest SEC filings
What Indivior Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Other event 8-K
- November 2, 2026
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 13% to $356M versus the same quarter last year; diluted EPS $1.12 versus $0.33.
- October 29, 2026Form 425 filing 425
- October 29, 2026
- October 15, 2026
- October 6, 2026Form 425 filing 425
- October 6, 2026Other event 8-K
- September 30, 2026Passive stake (5% or more) SCHEDULE 13G
- September 17, 2026Form 425 filing 425
Insider trades
What the people running Indivior Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $53.5K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Rubin JonathanSVP, Chief Medical Officer | Other change | 21,529 | - |
| November 2, 2026 | Khattar Jack A.Chief Executive Officer, Director | Other change | 1,937,986 | - |
| November 2, 2026 | Khattar Jack A.Chief Executive Officer, Director | Other changeindirect | 1,475,569 | - |
| November 2, 2026 | Gemayel GeorgesDirector | Other change | 42,009 | - |
| November 2, 2026 | Bhatt Padmanabh P.SVP of IP, CSO | Other change | 28,702 | - |
| November 2, 2026 | Barlow CarroleeDirector | Other change | 41,652 | - |
| November 2, 2026 | Dec Timothy CSVP, Chief Financial Officer | Other change | 14,059 | - |
| November 2, 2026 | Mottola FrankSVP, Chief Tech. Ops. Officer | Other change | 30,099 | - |
Who owns INDV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Portfolio Management13G, passive | 6.55% | April 28, 2026 |
| Millennium Management LLC13G, passive with 2 related filers | 5.4% | September 30, 2026 |
| Vanguard Capital Management13G, passive | 5.35% | April 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 338 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 18,709,432 | +167,212 |
| Vanguard Portfolio Management LLC | 7,572,287 | -319,532 |
| Oaktree Capital Management LP | 6,127,212 | -856,890 |
| Vanguard Capital Management LLC | 5,495,486 | -91,090 |
| State Street Corp | 4,992,071 | +88,078 |
| Fuller & Thaler Asset Management, Inc. | 4,615,816 | +86,233 |
| Two Seas Capital LP | 3,479,493 | -1,267,017 |
| Morgan Stanley | 3,395,702 | -110,115 |
| Franklin Resources Inc | 3,316,358 | +3,204,765 |
| Geode Capital Management, LLC | 3,159,866 | +234,178 |
| Assenagon Asset Management S.A. | 3,081,856 | new |
| Madison Avenue Partners, LP | 2,874,368 | -1,440,794 |
| Mangrove Partners IM, LLC | 2,676,730 | -65,704 |
| Citadel Advisors LLC | 2,667,827 | -906,217 |
| Driehaus Capital Management LLC | 2,299,054 | +419,015 |
| Millennium Management LLC | 2,098,945 | -2,496,590 |
| Dimensional Fund Advisors LP | 1,896,605 | +564,477 |
| Invesco Ltd. | 1,842,983 | +281,220 |
| Deerfield Management Company, L.P. | 1,648,895 | -1,448,895 |
| Arrowstreet Capital, Limited Partnership | 1,642,086 | -681,178 |
Insiders
20 insiders reported holding 5,200,876 shares in total, about $188.7M at the last price.
| Holder | Shares |
|---|---|
| Khattar Jack A.Chief Executive Officer, Director | 3,413,5551,475,569 held indirectly |
| Ciaffoni JosephChief Executive Officer, Director | 790,330 |
| Preblick RyanChief Financial Officer | 284,751 |
| Heidbreder ChristianChief Scientific Officer | 209,337 |
| Burris Jeffrey WChief Legal Officer | 71,518 |
| Wheadon David E.Director | 45,175 |
| Ninivaggi Daniel ADirector | 44,086 |
| Stejbach MarkDirector | 43,934 |
| Gemayel GeorgesDirector | 42,009 |
| Barlow CarroleeDirector | 41,652 |
Questions about INDV
What does Indivior Pharmaceuticals, Inc. do?
Indivior Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as INDV. Its shares trade on NASDAQ under the ticker INDV.
What is Indivior Pharmaceuticals, Inc.'s net worth?
Indivior Pharmaceuticals, Inc. has a market value (market cap) of $4.5B at the latest share price, and shareholders' equity of -$60M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Indivior Pharmaceuticals, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $451M on revenue of $1.4B, a net margin of 32.8%.
How much revenue does Indivior Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Indivior Pharmaceuticals, Inc. reported revenue of $1.4B.
When did Indivior Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 4, 2026.
When is Indivior Pharmaceuticals, Inc.'s next earnings report?
Indivior Pharmaceuticals, Inc.'s next report is expected around January 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare INDV with
Follow INDV
Get an email when Indivior Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Indivior Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.